This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Ppl Therapeutics (Scotland) Limited. Active years: 1997-1999.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1997-1999
Title: Alan Langskill Archibald: A Pioneer in Genetic Constructs
Introduction
Alan Langskill Archibald is a notable inventor based in Edinburgh, GB, recognized for his contributions to genetic engineering. With a total of two patents to his name, Archibald has made significant strides in the field, specifically related to the production of proteinaceous products through innovative genetic constructs.
Latest Patents
Archibald’s latest patents focus on a genetic construct designed to enhance protein production in transgenic animals. The patented construct integrates a DNA sequence that comprises introns and employs a 5'-flanking sequence from a mammalian milk protein gene, such as beta-lactoglobulin. This innovative approach enables the expression of heterologous proteins, such as serin proteases and blood factors like Factors VIII and IX, leveraging the existing cellular machinery of the host animal. The unique aspect of his invention is that the protein-coding DNA includes at least one intron from the gene coding for the heterologous protein, allowing effective expression driven by the specifically engineered flanking sequence.
Career Highlights
Archibald has built a commendable career at PPL Therapeutics (Scotland) Limited, where he has been instrumental in advancing biotechnological innovations. His work primarily revolves around the interface of genetic engineering and transgenic technology, contributing to advancements that hold significant potential for therapeutic applications in medicine and agriculture.
Collaborations
Throughout his career, Archibald has collaborated with notable professionals in his field, including Anthony John Clark and Stephen Harris. These collaborations have fostered a dynamic environment at PPL Therapeutics, driving shared innovations and fostering breakthroughs in genetic research.
Conclusion
Alan Langskill Archibald exemplifies the spirit of innovation in the realm of genetic engineering. His patented work enables advancements in producing essential proteins, paving the way for future therapies and applications. As he continues to push the boundaries of science, Archibald remains a significant figure in the field of biotechnology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile